INTRODUCTION & OBJECTIVES:
Although randomized prospective data demonstrated no benefit in performing lymph node dissection (LND) at the time of nephrectomy in cN0 disease, some retrospective studies support its use in certain clinical scenarios. Recent reports suggested underuse of LND in the United States, where today less than 20% of the patients undergo LND at the time of nephrectomy. We 2% from 1985 to 2008 vs. 23.4-30.1% after 2008 (p<0.0001) . This decline was also driven by stage migration to low stage diseases, use of minimally invasive surgery, and centers' disparities.
CONCLUSIONS: There has been a significant decline in LND rates for kidney cancer over the past years. LND is more frequently performed in younger patients, locally advanced diseases, and open surgery with significant disparities among centers. Although declining, unstandardized and limited in its extension, LND is still more frequently performed in Europe than in the United States.
